NYSE · Healthcare
RESMED INC (RMD)
As-reported financials and recent SEC filings for RESMED INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$5.15B
Net income
$1.40B
Net margin
27.2%
Diluted EPS
$9.51
ROE
23.5%
P/E (TTM)
19.3×
Market cap
$29.05B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B |
| Gross profit | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B |
| Operating income | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M |
| Net income | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M |
| Diluted EPS | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-09
View on EDGAR →1442026-06-08
View on EDGAR →42026-06-03
View on EDGAR →1442026-05-27
View on EDGAR →SD2026-05-26
View on EDGAR →42026-05-11
View on EDGAR →1442026-05-07
View on EDGAR →32026-05-04
View on EDGAR →Go deeper on RMD
Search RESMED INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.